Rankings / Cognitive

Blarcamesine (ANAVEX 2-73)

Cognitive · Sigma-1 receptor agonist (autophagy)

Tier D+

Reviewed by Read Off Label · Last reviewed · How we grade

alzheimersigma-1autophagyinvestigational
3.7 / 10
Tier D+
Ev 3 Bn 2 Sf 5

Bottom line

Read Off Label grades Blarcamesine (ANAVEX 2-73) as D+ (3.7/10) based on weak evidence, low benefit magnitude, and a med-risk safety profile.

Anavex's lead drug — a sigma-1 agonist betting on autophagy enhancement instead of amyloid clearance, which also draws longevity interest since autophagy is a core aging pathway.

Typical use: Oral once daily; Phase 3 used titrated doses (~30-50 mg/day) — Investigational.

What this is

Anavex's lead drug — a sigma-1 agonist betting on autophagy enhancement instead of amyloid clearance, which also draws longevity interest since autophagy is a core aging pathway. Phase 2b/3 AD-004 (ATTENTION-AD) in early Alzheimer's showed only modest, subgroup-dependent slowing (greatest in SIGMAR1/COL24A1 wild-type patients) plus a brain-volume signal presented at AD/PD 2026. The EMA's CHMP recommended refusal in Dec 2025 and Anavex withdrew the European application on 25 Mar 2026; the FDA gave NDA-pathway feedback Jan 2026. Heavily hyped in biohacker/longevity circles for the autophagy mechanism, but the regulatory verdict so far is skeptical and the human benefit is marginal. Included for an honest read, not an endorsement.

Mechanism

Oral small-molecule sigma-1 receptor (SIGMAR1) agonist that enhances autophagy and cellular homeostasis; aims to slow neurodegeneration rather than clear amyloid

Dose & route

Oral once daily; Phase 3 used titrated doses (~30-50 mg/day)

Citations

Links go to the source. If a link is dead or you want something re-checked, let me know.

Common questions

Does Blarcamesine (ANAVEX 2-73) work?
Read Off Label rates the evidence for Blarcamesine (ANAVEX 2-73) as Weak and the benefit magnitude as low, producing an overall grade of D+ (3.7/10). Anavex's lead drug — a sigma-1 agonist betting on autophagy enhancement instead of amyloid clearance, which also draws longevity interest since autophagy is a core aging pathway.
Is Blarcamesine (ANAVEX 2-73) safe?
Blarcamesine (ANAVEX 2-73) has a med risk profile in published human data. Legal status: Investigational (EMA MAA withdrawn Mar 2026 after negative opinion; FDA NDA pathway under discussion). This is not medical advice — see the disclaimer.
What is the typical dose for Blarcamesine (ANAVEX 2-73)?
Oral once daily; Phase 3 used titrated doses (~30-50 mg/day)
How does Blarcamesine (ANAVEX 2-73) work?
Oral small-molecule sigma-1 receptor (SIGMAR1) agonist that enhances autophagy and cellular homeostasis; aims to slow neurodegeneration rather than clear amyloid

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.